𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate cancer vaccines in clinical trials

✍ Scribed by Lubaroff, David M

Book ID
115459298
Publisher
Expert Reviews
Year
2012
Tongue
English
Weight
719 KB
Volume
11
Category
Article
ISSN
1476-0584

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Allogeneic retrovirally transduced, IL-2
Allogeneic retrovirally transduced, IL-2- and IFN-Ξ³-secreting cancer cell vaccine in patients with hormone refractory prostate cancerβ€”a phase I clinical trial
✍ T. H. Brill; H. R. KΓΌbler; H. v. Randenborgh; F. Fend; H. Pohla; J. Breul; R. Ha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 856 KB

## Abstract ## Background The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant interleukin‐2 (IL‐2) and interferon‐γ (IFN‐γ) and to evaluate the efficacy of inducing tumor‐specifi

Interpreting cancer vaccine clinical tri
Interpreting cancer vaccine clinical trials
✍ Glenn Dranoff πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 53 KB πŸ‘ 2 views

A number of cancer vaccine strategies have entered initial Phase I clinical testing. In this review, Dr. Glenn Dranoff discusses the prospects that appropriate immunologic monitoring of patients in these trials can help delineate important differences among the various immunization strategies and pr